Lanreotide
An FDA-approved long-acting somatostatin analog used to treat acromegaly, gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome.
What is Lanreotide?
Lanreotide is a synthetic cyclic octapeptide analog of somatostatin developed by Ipsen, with high affinity for somatostatin receptor subtypes SSTR2 and SSTR5. It is FDA-approved for long-term treatment of acromegaly (2007), gastroenteropancreatic neuroendocrine tumors (GEP-NETs, 2014, based on the CLARINET trial), and carcinoid syndrome (2014). Its signature formulation — the Autogel/Depot supersaturated aqueous gel in a pre-filled syringe — enables once-monthly deep subcutaneous administration, distinguishing it from octreotide LAR's intramuscular microsphere depot.
What Lanreotide Is Investigated For
Lanreotide is an FDA-approved long-acting somatostatin analog with three core indications: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome. The strongest evidence base sits in GEP-NETs, where the pivotal CLARINET trial (Caplin et al., NEJM 2014) demonstrated a significant progression-free survival benefit versus placebo in patients with advanced, well- or moderately differentiated, non-functioning, somatostatin-receptor-positive grade 1–2 tumors (hazard ratio 0.47; median PFS not reached vs. 18 months on placebo). In acromegaly, multiple phase 3 trials and long-term registry data (including the LANTERN, SODA, and original Autogel pivotal programs) show biochemical control comparable to octreotide LAR. In carcinoid syndrome, the ELECT phase 3 trial confirmed lanreotide's ability to reduce the need for short-acting octreotide rescue dosing and to control flushing and diarrhea symptoms. This is emphatically not a wellness peptide. Its side-effect profile — cholelithiasis, glycemic dysregulation, injection-site reactions, sinus bradycardia, and GI symptoms — warrants specialist supervision, and its use belongs in endocrinology or oncology clinics, not compounded-peptide settings. Off-label use for performance or aesthetic purposes has no evidence base and carries real risk.
History & Discovery
Lanreotide was developed by the French-British biopharmaceutical company Ipsen (originally as part of Beaufour-Ipsen) in the 1980s, emerging from the same wave of somatostatin-analog medicinal chemistry that produced octreotide at Sandoz. Native somatostatin — identified by Roger Guillemin's group in the early 1970s — has a two-minute plasma half-life, making direct therapeutic use impractical. Ipsen's answer, BIM-23014 (lanreotide), is a cyclic octapeptide with D-amino-acid substitutions and a disulfide bridge that preserve SSTR2 and SSTR5 binding while resisting proteolysis. The first commercial formulation, Somatuline LA (lanreotide prolonged-release, 30 mg intramuscular every 7–14 days), reached European markets in the mid-1990s and was approved across the EU for acromegaly. Its most distinctive innovation, however, was the Autogel/Depot formulation — a supersaturated aqueous gel in which lanreotide acetate self-assembles into a semi-solid depot at physiological temperature after deep subcutaneous injection, releasing drug over approximately 28 days without the microsphere or polymer excipients used by octreotide LAR. The Autogel was launched in Europe in 2001 and offered two practical advantages over octreotide LAR: a smaller pre-filled syringe (deep SC rather than IM), and — with training — the option for patient or partner administration at home. In the United States, the regulatory path was longer. The FDA first approved Somatuline Depot for acromegaly in August 2007. The transformative approvals came in December 2014: on the strength of the pivotal phase 3 CLARINET trial (Caplin et al., NEJM 2014), the FDA approved Somatuline Depot for the treatment of unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), alongside approval for carcinoid syndrome (on the basis of the ELECT trial). The CLARINET indication was particularly consequential because it established somatostatin-analog therapy as an anti-proliferative intervention — not just a symptomatic one — in advanced NETs, shifting first-line standard of care. Lanreotide and octreotide have since coexisted as the two dominant long-acting somatostatin analogs, with broadly similar efficacy in head-to-head comparisons and differences largely driven by formulation, administration route, and patient preference. More recently, multi-receptor somatostatin analogs (pasireotide, which also binds SSTR1 and SSTR3) have entered the space for patients with incomplete response to lanreotide or octreotide, and radiolabeled analogs (Lutathera / [177Lu]-DOTATATE) have extended somatostatin-receptor-targeted therapy into peptide receptor radionuclide therapy for NETs.
How It Works
Lanreotide mimics somatostatin, the body's natural brake on multiple hormones. It binds tightly to somatostatin receptors on the pituitary, pancreas, and neuroendocrine tumor cells, switching off excess hormone release and — in certain tumors — slowing tumor growth.
Lanreotide is a cyclic octapeptide with D-amino-acid substitutions and a disulfide bridge that confer protease resistance. It binds with high affinity to somatostatin receptor subtypes SSTR2 and SSTR5, with lower affinity for SSTR3 and minimal binding to SSTR1 and SSTR4 — a selectivity profile nearly identical to octreotide. SSTR activation inhibits adenylyl cyclase via Gi coupling, reducing intracellular cAMP, closing voltage-gated calcium channels, and activating potassium channels, which collectively suppress hormone exocytosis. Downstream this reduces pituitary GH secretion, IGF-1 production, and the release of insulin, glucagon, VIP, gastrin, serotonin, and other gut hormones. In neuroendocrine tumors, SSTR-mediated signaling also produces direct anti-proliferative effects through cell-cycle arrest and modulation of apoptotic pathways. The Autogel/Depot formulation is a supersaturated aqueous gel (lanreotide acetate in water, with no excipient-based delayed-release mechanism) that self-assembles into a depot after deep subcutaneous injection, releasing drug over approximately 28 days.
Evidence Snapshot
Human Clinical Evidence
Extensive. Pivotal RCTs in NETs (CLARINET), carcinoid syndrome (ELECT), and multiple phase 3 acromegaly trials, plus two decades of registry and real-world data.
Animal / Preclinical
Comprehensive. Somatostatin-receptor pharmacology is among the best-characterized peptide hormone systems.
Mechanistic Rationale
Very strong. SSTR2/5 agonism is a well-understood mechanism for both hormone suppression and NET anti-proliferative effect.
Research Gaps & Open Questions
What the current literature has not yet settled about Lanreotide:
- 01Optimal sequencing and combination with newer NET agents — CLARINET established anti-proliferative benefit as monotherapy, but the best sequencing of lanreotide with Lutathera/PRRT, everolimus, sunitinib, and capecitabine/temozolomide in advanced or progressing NETs is still being refined.
- 02Extended-interval dosing in well-controlled acromegaly — some patients tolerate dosing every 6–8 weeks without loss of biochemical control; formal dose-extension protocols are not standardized, and predictors of eligibility are underdeveloped.
- 03Direct head-to-head RCTs with octreotide LAR — existing comparisons are largely indirect, crossover, or observational; a well-powered modern RCT comparing lanreotide Depot to octreotide LAR with matched dosing in treatment-naïve acromegaly or NET populations would resolve lingering questions about true equivalence.
- 04High-dose and shortened-interval regimens — dose escalation to 120 mg every 2 weeks is used clinically in refractory carcinoid syndrome and in some NET progression settings, but randomized evidence for this strategy remains limited.
- 05Predictive biomarkers — beyond baseline SSTR expression on imaging (68Ga-DOTATATE PET), biomarkers predicting individual magnitude of biochemical or anti-proliferative response to lanreotide are not well established.
- 06Long-term safety beyond 5–10 years — while two decades of clinical use provide reassurance, prospective long-term data on gallstone outcomes, cumulative glycemic effects, and cardiovascular signals in chronically treated populations are still accruing.
- 07Comparative performance versus pasireotide in mixed SSTR-expressing tumors — pasireotide's broader SSTR1/3 binding produces better response in some acromegaly and Cushing's populations but worse glycemic profile; patient-selection criteria for switching are incompletely defined.
Forms & Administration
Lanreotide Autogel/Depot is supplied as a pre-filled syringe at 60 mg, 90 mg, or 120 mg, administered by deep subcutaneous injection (typically in the upper outer quadrant of the buttock) every 4 weeks. Acromegaly dosing is titrated based on GH/IGF-1 response; NET and carcinoid dosing is typically 120 mg every 4 weeks. After appropriate training, the injection can be administered by a caregiver or self-administered, which is a practical advantage over intramuscular octreotide LAR. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Lanreotide Autogel/Depot is supplied as a pre-filled syringe at 60 mg, 90 mg, or 120 mg. For acromegaly, the typical starting dose is 90 mg every 4 weeks, with titration based on GH and IGF-1 response: 60 mg if IGF-1 is within 1.3× upper limit of normal and GH suppressed, up to 120 mg if IGF-1 remains elevated. For GEP-NETs and carcinoid syndrome, the label dose is 120 mg every 4 weeks from the outset. Extended dosing intervals (every 6–8 weeks) have been studied in selected well-controlled acromegaly patients but are not standard.
Frequency
Once every 4 weeks by deep subcutaneous injection, typically into the upper outer quadrant of the buttock. The pre-filled syringe design allows administration by a trained healthcare provider, patient, or partner after instruction — a practical advantage over intramuscular octreotide LAR, which is administered by a clinician.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Lanreotide is a chronic, indefinite therapy for acromegaly (biochemical control), GEP-NETs (anti-proliferative tumor stabilization), and carcinoid syndrome (symptom control). There is no cycling in the wellness-protocol sense. Treatment continues as long as benefit is demonstrated and tolerated; discontinuation is generally followed by return of hypersecretion or tumor progression.
Protocol Notes
Deep subcutaneous injection technique matters — the needle must reach the deep subcutaneous tissue for the supersaturated gel to form a stable depot. Improper technique (too superficial) is associated with induration, nodules, and erratic pharmacokinetics. Injection-site rotation between buttock quadrants is standard. Cholelithiasis is the most clinically important long-term complication. Lanreotide, like octreotide, reduces gallbladder motility and shifts bile composition toward stone formation; gallstones develop in a meaningful minority of long-term users, with risk rising with treatment duration. Baseline gallbladder ultrasound and periodic (typically annual) surveillance imaging is standard practice. Glycemic effects are biphasic. Lanreotide suppresses both insulin and glucagon. In acromegaly, GH/IGF-1 normalization often improves insulin resistance; however, new-onset hyperglycemia or worsening of pre-existing diabetes is common, and hypoglycemia can occur in insulin-dependent patients. Glucose monitoring is part of routine follow-up, with more intensive monitoring for diabetic patients, especially during initiation and dose changes. For NET management, the 120 mg every-4-weeks dose is standard; some protocols use shorter intervals (every 14 days) in breakthrough symptom flares or as a bridge before PRRT. When patients transition to radiolabeled somatostatin analog therapy (Lutathera), lanreotide is typically withheld in the days surrounding each PRRT infusion to avoid receptor occupancy competing with the radiolabeled peptide — protocol-specific guidance should be followed. The pre-filled syringe must be stored refrigerated (2–8°C) in its original packaging; it may be kept at room temperature for up to 24 hours prior to administration.
Lanreotide is FDA-approved for long-term treatment of acromegaly, unresectable GEP-NETs, and carcinoid syndrome. It is a specialty medication that should be prescribed and monitored by an endocrinologist, oncologist, or other specialist familiar with somatostatin-analog therapy. Off-label or cosmetic use is not supported by evidence.
Timeline of Effects
Onset
After a single deep subcutaneous injection of lanreotide Autogel, plasma concentrations rise over the first 24–48 hours and then plateau for the 4-week dosing interval. Clinical effects follow the pharmacology: GH suppression in acromegaly is detectable within days, and symptom relief in carcinoid syndrome (reduced flushing, less diarrhea) is typically reported within the first 1–2 weeks. Because the depot does not require immediate-release overlap (unlike octreotide LAR), dose-finding is simpler but requires waiting through one dosing cycle to assess.
Peak Effect
Steady-state plasma concentrations are generally reached after 3–4 monthly injections (approximately 12–16 weeks), which is the standard assessment point for biochemical response in acromegaly (IGF-1, GH) and for symptom/tumor response in NETs. In CLARINET, progression-free survival curves diverged within the first 6 months and continued to separate through 24 months. In ELECT, symptom control versus placebo was apparent across the initial 16-week double-blind phase and sustained through the 32-week open-label extension.
After Discontinuation
The functional half-life of lanreotide from the depot is approximately 25 days; plasma concentrations decline over 4–8 weeks after the last injection as the depot is exhausted. Underlying disease activity — acromegalic GH/IGF-1 hypersecretion, NET growth, or carcinoid symptoms — typically returns to pretreatment levels in parallel. There is no disease-modifying benefit that persists after discontinuation; rebound symptom worsening is expected in carcinoid syndrome if dosing lapses, and IGF-1 creeps back up in acromegaly over weeks to months.
Common Questions
Who Lanreotide Is NOT For
- •Known hypersensitivity to lanreotide or to any formulation excipient.
- •Pregnancy — not generally recommended; somatostatin analogs cross the placenta and may affect fetal growth-hormone signaling. Specialist consultation is required and effective contraception is advised for patients of childbearing potential.
- •Breastfeeding — limited data on transfer into breast milk; clinical decisions are individualized.
- •Pre-existing significant gallstone disease or recurrent biliary symptoms — relative contraindication; reduced gallbladder motility on lanreotide aggravates stone formation risk.
- •Severe hepatic impairment — pharmacokinetic alterations may require dose adjustment; advanced cirrhosis is a relative contraindication.
- •Brittle or insulin-dependent diabetes without close glucose monitoring — glycemic dysregulation is common and both hyper- and hypoglycemia can occur.
- •Significant bradycardia or cardiac conduction abnormalities — lanreotide can produce sinus bradycardia and conduction-system changes; ECG monitoring may be warranted in at-risk patients.
- •Severe renal impairment — dose consideration required; the terminal half-life is modestly prolonged but dose adjustment is generally not required for mild-to-moderate impairment.
Drug & Supplement Interactions
Lanreotide produces several clinically relevant drug interactions, most of which mirror the octreotide profile given shared SSTR2/5 pharmacology. Cyclosporine: lanreotide reduces cyclosporine absorption, potentially leading to subtherapeutic immunosuppression. In transplant patients, this is the single most clinically important documented interaction and requires close drug-level monitoring and dose adjustment. Insulin and oral antihyperglycemics: lanreotide alters glucose homeostasis by suppressing both insulin and glucagon. Antidiabetic regimens frequently require dose adjustment during initiation and dose changes, with both hypoglycemia and hyperglycemia possible depending on the underlying diabetic phenotype. Bromocriptine and dopamine agonists: in acromegaly, combination therapy is sometimes used, and lanreotide may increase bromocriptine exposure. Additive effects on GH/IGF-1 suppression are expected; combination regimens warrant specialist oversight. Beta blockers, calcium channel blockers, and other agents affecting cardiac conduction: additive bradycardia risk warrants ECG monitoring in at-risk patients. CYP3A4-metabolized drugs with narrow therapeutic indices (warfarin, quinidine): lanreotide may slow hepatic metabolism through reduced GH-driven CYP activity. Close monitoring is appropriate, though the magnitude of effect is modest. For NET patients on or being considered for peptide receptor radionuclide therapy (Lutathera / [177Lu]-DOTATATE), the timing of long-acting lanreotide relative to PRRT infusion follows protocol-specific guidance to avoid receptor competition with the radiolabeled peptide — typically lanreotide is held for a defined interval before and after PRRT administration.
Safety Profile
Common Side Effects
Cautions
- • Baseline and periodic gallbladder ultrasound is standard
- • Glucose monitoring required, especially in diabetic patients
- • Sinus bradycardia and cardiac conduction changes possible
- • Drug interaction with cyclosporine (reduced absorption)
What We Don't Know
Well-characterized safety profile with two decades of clinical use across acromegaly and NET populations.
Legal Status
United States
Lanreotide (Somatuline Depot) is FDA-approved. Initial US approval was August 2007 for long-term treatment of acromegaly when surgery or radiotherapy are inadequate or not options. In December 2014, the FDA approved two additional indications on a single day: (1) treatment of unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival, based on the CLARINET trial, and (2) treatment of carcinoid syndrome, based on the ELECT trial. It is a prescription-only specialty medication, not a controlled substance, dispensed through specialty pharmacy networks.
International
Approved in the EU (Somatuline Autogel, first launched 2001), UK, Canada, Japan, Australia, and most major markets for acromegaly, NETs, and carcinoid syndrome. The Autogel formulation is the dominant global formulation; earlier prolonged-release formulations (Somatuline LA) have been largely phased out.
Sports & Competition
Lanreotide is not specifically named on the WADA Prohibited List. However, because growth-hormone suppression is central to its pharmacology, athletes considering it should consult anti-doping authorities directly. Legitimate therapeutic use under documented indication and Therapeutic Use Exemption is typically not problematic; off-label performance-related use is uncommon and poorly characterized in anti-doping casework.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Lanreotide and octreotide are the same drug with different branding.
Reality
They are distinct molecules from different manufacturers (Ipsen vs. originally Sandoz/Novartis), with overlapping but not identical pharmacology. Both are synthetic cyclic octapeptide somatostatin analogs with high SSTR2/5 affinity, and they are broadly similar in clinical effect, but lanreotide Autogel is a supersaturated aqueous gel given deep subcutaneously every 4 weeks, while octreotide LAR is a microsphere depot given intramuscularly every 4 weeks. Subtle pharmacokinetic and adverse-event differences exist, and switching between them in either direction requires biochemical reassessment rather than dose-equivalence assumption.
Myth
Since CLARINET showed PFS benefit, lanreotide shrinks GEP-NET tumors.
Reality
CLARINET demonstrated progression-free survival benefit — lanreotide slowed tumor progression relative to placebo. Objective tumor shrinkage (RECIST partial or complete response) is uncommon with somatostatin-analog monotherapy in NETs; the benefit is predominantly disease stabilization. This distinction matters for patient counseling and for choosing between lanreotide and agents with higher response rates (e.g., PRRT, chemotherapy) in rapidly progressing disease.
Myth
If octreotide stops working, switching to lanreotide will restore response.
Reality
Because both target the same receptors (SSTR2 and SSTR5) with comparable affinity, a patient who has escaped octreotide control is unlikely to recapture durable control with lanreotide at equivalent doses. Options in that setting include dose escalation, shortened dosing intervals, switching to the multi-receptor analog pasireotide (broader SSTR coverage), adding an adjunctive agent, or advancing to PRRT for NETs. The lanreotide-for-octreotide swap is reasonable for administration or tolerability reasons, not for rescuing a biochemically escaped patient.
Myth
Lanreotide's subcutaneous injection route makes it safer than intramuscular octreotide LAR.
Reality
The route affects injection technique and administration logistics, not the systemic safety profile. The main adverse events — cholelithiasis, glycemic dysregulation, GI symptoms, bradycardia, injection-site reactions — occur with both agents and reflect shared somatostatin-receptor pharmacology. Recent comparative pharmacovigilance analyses suggest modest differences in injection-site reactions and GI signals, but the systemic safety envelope is substantively similar.
Myth
Lanreotide is a useful weight-loss or anti-aging peptide because it suppresses growth hormone.
Reality
Lanreotide's GH suppression is therapeutic in acromegaly, where GH excess is pathological. In healthy adults, suppressing GH and IGF-1 does not produce favorable metabolic outcomes — physiological GH supports lean mass, bone density, and normal metabolism. Lanreotide additionally suppresses insulin and glucagon, produces gallstones, and causes GI side effects. There is no legitimate wellness indication for it outside specialist-supervised therapy for approved diseases.
Published Research
19 studiesComparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases
Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study
Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)
The safety of lanreotide for neuroendocrine tumor
Lanreotide therapy in carcinoid syndrome: prospective analysis of patient-reported symptoms in patients responsive to prior octreotide therapy and patients naïve to somatostatin analogue therapy in the ELECT phase 3 study
Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials
A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry
Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors
Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (ELECT): A Randomized, Double-Blind, Placebo-Controlled Trial
The phase 3 ELECT trial randomized patients with carcinoid syndrome (with or without prior somatostatin analog exposure) to lanreotide Depot/Autogel 120 mg or placebo every 4 weeks over 16 weeks, with short-acting octreotide available as rescue. Lanreotide significantly reduced the percentage of days requiring rescue octreotide and decreased flushing and diarrhea frequency versus placebo, with benefits sustained through 32 weeks of open-label extension. ELECT supported the 2014 FDA approval of lanreotide for carcinoid syndrome and established it as a non-inferior alternative to octreotide LAR for symptom control.
Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
Lanreotide autogel: a review of its use in the treatment of patients with acromegaly
Lanreotide in metastatic enteropancreatic neuroendocrine tumors (CLARINET)
The pivotal phase 3 CLARINET trial (Caplin et al., NEJM 2014) — the foundation for the 2014 FDA approval of lanreotide Depot in GEP-NETs. This randomized, double-blind, placebo-controlled study in 204 patients with advanced, well- or moderately differentiated, non-functioning, somatostatin-receptor-positive grade 1–2 enteropancreatic NETs showed median progression-free survival not reached on lanreotide 120 mg every 4 weeks vs. 18.0 months on placebo (hazard ratio 0.47, P<0.001), with 24-month PFS rates of 65.1% vs. 33.0%. CLARINET established the anti-proliferative (not just symptomatic) role of somatostatin analogs in NET care and changed standard first-line therapy for this population.
Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly
Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly
Long-acting somatostatin analog therapy of acromegaly: a meta-analysis
Quick Facts
- Class
- Somatostatin Analog / SSTR2/5 Agonist
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Apr 2026
- Citations
- 19PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.